文献速递消化道肿瘤放疗放疗物理与技术

新辅助SBRT联合卡培他滨及选择性淋巴结照射治疗可切除胰腺癌的1期剂量递增研究

A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-09-14

该前瞻性1期剂量递增研究纳入可切除胰头癌患者,采用4+4设计评估新辅助SBRT(5次5–7 Gy)联合卡培他滨及选择性淋巴结照射(ENI,25 Gy/5次)的毒性和可行性。17例入组、16例可评估,未出现剂量限制性毒性,SBRT最大递增至35 Gy/5次(8例),13例手术者均R0切除。

要点

  • 新辅助SBRT联合卡培他滨及ENI未出现剂量限制性毒性,最大递增至35 Gy/5次。
  • 最常见毒性为恶心(56%),13例手术患者均实现R0切除。
  • 7例(54%)病理标本显示中度治疗效应,3例(23%)出现局部区域复发。

核心结论

  • 新辅助SBRT联合卡培他滨及ENI可安全递增至35 Gy/5次,该方案将用于未来扩展队列。

研究设计与样本

  • 前瞻性1期剂量递增研究,采用4+4设计,纳入活检证实的可切除胰头癌患者。
  • SBRT为5次5–7 Gy,同步卡培他滨,所有剂量水平均联合ENI 25 Gy/5次。
  • 最大耐受剂量水平扩展额外4例,共17例入组、16例可评估。

主要发现

  • 最常见毒性为恶心(56%),未出现剂量限制性毒性。
  • SBRT最大递增至35 Gy/5次,共8例接受该剂量。
  • 13例最终手术,全部R0切除;7例(54%)病理标本显示中度治疗效应。
  • 3例(23%)出现局部区域复发,其中2例(15%)部分位于治疗体积内。

关键数值与推荐

  • 剂量限制性毒性定义为SBRT后90天内归因于放化疗的任何≥3级非血液学毒性(NCI CTCAE v4.0)。
  • ENI剂量为25 Gy/5次,SBRT剂量水平为5次5–7 Gy。

临床怎么用

  • 该方案可行性支持新辅助SBRT联合卡培他滨及ENI用于可切除胰腺癌,需进一步扩展队列验证。

局限性

  • 1期小样本剂量递增研究,主要评估毒性和可行性,疗效需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The role of neoadjuvant radiation for resectable pancreatic adenocarcinoma is controversial. We performed a prospective dose-escalation study of neoadjuvant stereotactic body radiation therapy (SBRT) with concurrent capecitabine and elective nodal irradiation (ENI) followed by surgical resection to explore the toxicity and feasibility of this approach. METHODS AND MATERIALS: Patients with biopsy proven, resectable cancers of the pancreatic head were enrolled. A 4 + 4 dose-escalation design was employed delivering 5 fractions of 5 to 7 Gy to primary tumor with concurrent capecitabine. The maximum tolerated dose level was expanded for an additional 4 patients. Patients at all dose levels were treated with ENI delivering 25 Gy in 5 fractions. Dose-limiting toxicity was defined as any grade ≥3 nonhematologic toxicity (National Cancer Institute Common Terminology Criteria for Adverse Events v4.0) attributable to chemoradiation occurring within 90 days of SBRT. RESULTS: A total of 17 patients were enrolled with 16 patients evaluable and 13 patients ultimately proceeding to surgery. The most common toxicity was nausea (56%). There were no dose-limiting toxicities, and SBRT was maximally dose escalated to 35 Gy in 5 fractions for 8 patients. All patients completing surgery had R0 resections. Seven patients (54%) had moderate treatment effect identified in pathologic specimens. Three patients (23%) developed locoregional recurrences, with 2 (15%) partially included within the treated volume. CONCLUSIONS: SBRT was safely dose escalated to 35 Gy in 5 fractions along with concurrent capecitabine and ENI. This regimen will be used in a future expansion cohort.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Witt JS, Kuczmarska-Haas A, Lubner M, et al. A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2020. PMID: 32942002. doi:10.1016/j.ijrobp.2020.09.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。